Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ascendis Pharma A/S - Ordinary Share
(NQ:
ASND
)
249.02
+0.04 (+0.02%)
Delayed Quote
Updated: 11:49 AM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ascendis Pharma A/S - Ordinary Share
< Previous
1
2
3
4
5
6
7
8
9
Next >
Ascendis Pharma (NASDAQ:ASND): Strong Growth Meets a High-Quality Technical Setup
↗
September 14, 2026
Via
Chartmill
Ascendis Pharma (NASDAQ:ASND): A Fitting Candidate for Affordable Growth Investors
↗
September 09, 2026
Via
Chartmill
Ascendis Pharma (NASDAQ:ASND) Passes Minervini Trend Template and High Growth Momentum Screen
↗
September 01, 2026
Via
Chartmill
If You Invested $1000 In Ascendis Pharma Stock 10 Years Ago, You Would Have This Much Today
↗
August 26, 2026
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 16.69% on an annualized basis producing an average annual return of 30.07%. Currently, Ascendis Pharma has a market...
Via
Benzinga
Ascendis Pharma (ASND) Q2 2026 Earnings Call Transcript
↗
August 20, 2026
Revenue surged 105% year-over-year as three approved products scale globally.
Via
The Motley Fool
Topics
Earnings
Ascendis Pharma (NASDAQ:ASND) Combines High Growth Momentum with a Breakout Setup
↗
August 11, 2026
Via
Chartmill
Ascendis Pharma (ASND) Shows High Growth Momentum With Bull Flag Breakout Setup
↗
July 20, 2026
Via
Chartmill
ASCENDIS PHARMA A/S (NASDAQ:ASND) Screens as a High-Growth Momentum Candidate
↗
May 18, 2026
Via
Chartmill
Ascendis Pharma (NASDAQ:ASND) Shares Drop After Q4 Earnings Miss on Wider-Than-Expected Loss
↗
February 11, 2026
Via
Chartmill
Topics
Earnings
Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients
August 18, 2026
From
Eyconis Inc.
Via
GlobeNewswire
Ascendis Pharma A/S Q2 Earnings Call Highlights
↗
August 13, 2026
Ascendis Pharma A/S (NASDAQ:ASND) reported second-quarter 2026 total revenue of EUR 339 million, including EUR 315 million in product revenue, as demand for its three commercial TransCon-based...
Via
MarketBeat
Topics
Earnings
Here's How Much $100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth Today
↗
August 11, 2026
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 5 years by 5.62% on an annualized basis producing an average annual return of 17.21%. Currently, Ascendis Pharma has a market...
Via
Benzinga
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma
↗
May 14, 2026
Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology.
Via
The Motley Fool
Topics
Regulatory Compliance
ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Minervini Trend Template with High Growth Momentum
↗
January 28, 2026
Via
Chartmill
Earnings Scheduled For November 12, 2025
↗
November 12, 2025
Via
Benzinga
Energy Fund Yielding 7% and Up 14% in a Year Still Wasn’t Enough to Stop This $3 Million Exit
↗
May 09, 2026
The Kayne Anderson Energy Infrastructure Fund targets U.S. energy infrastructure, emphasizing income from MLPs and related equities.
Via
The Motley Fool
Topics
Regulatory Compliance
Ascendis (ASND) Q1 2026 Earnings Call Transcript
↗
May 08, 2026
Ascendis (ASND) Q1 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity
April 13, 2026
In a move that signals a transformative shift from a clinical-stage biotech to a commercial-market leader, Ascendis Pharma (NASDAQ: ASND) officially launched its third major product, YUVIWEL...
Via
MarketMinute
Topics
Economy
Agriculture Stock Up 53% Draws $12 Million Bet. Here's What Long-Term Investors Should Know
↗
March 20, 2026
This agribusiness firm delivers grain, renewables, and plant nutrient solutions to commercial and industrial clients worldwide.
Via
The Motley Fool
Topics
Regulatory Compliance
Ascendis (ASND) Q4 2025 Earnings Call Transcript
↗
February 23, 2026
Ascendis (ASND) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million
↗
February 22, 2026
Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position
↗
February 22, 2026
Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.
Via
The Motley Fool
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction
↗
February 22, 2026
Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.
Via
The Motley Fool
Topics
Regulatory Compliance
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges
↗
February 22, 2026
Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.
Via
The Motley Fool
Topics
Regulatory Compliance
Ascendis Pharma (ASND) Q4 2025 Earnings Transcript
↗
February 11, 2026
Ascendis Pharma (ASND) Q4 2025 Earnings Transcript
Via
The Motley Fool
Ascendis Pharma (NASDAQ:ASND) Passes Minervini's Trend Template and High Growth Momentum Scan
↗
December 25, 2025
Ascendis Pharma (ASND) meets Mark Minervini's strict criteria, showing a powerful technical uptrend paired with explosive revenue growth over 269%.
Via
Chartmill
Why Dyne Therapeutics Stock Was Crushing it This Week
↗
November 21, 2025
The company has solid potential with its development of drugs targeting muscle disorders.
Via
The Motley Fool
Topics
Artificial Intelligence
European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility
November 19, 2025
European American Depositary Receipts (ADRs) have recently experienced a period of significant fluctuation, reflecting a broader climate of market volatility that has ripple across global financial...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Supply Chain
Ascendis (ASND) Q3 2025 Earnings Call Transcript
↗
November 13, 2025
Ascendis (ASND) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
↗
November 12, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
